Investors with a lot of money to spend have taken a bearish stance on Liquidia (NASDAQ:LQDA).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LQDA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 24 uncommon options trades for Liquidia.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 41%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $163,755, and 19 are calls, for a total amount of $2,788,877.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $47.5 for Liquidia over the recent three months.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Liquidia stands at 3181.0, with a total volume reaching 19,200.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Liquidia, situated within the strike price corridor from $25.0 to $47.5, throughout the last 30 days.
Liquidia Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | CALL | TRADE | BULLISH | 04/17/26 | $17.7 | $15.0 | $17.2 | $27.50 | $344.0K | 1.7K | 200 |
| LQDA | CALL | TRADE | BULLISH | 04/17/26 | $18.0 | $15.5 | $17.1 | $27.50 | $342.0K | 1.7K | 400 |
| LQDA | CALL | TRADE | BEARISH | 01/30/26 | $5.0 | $3.8 | $4.2 | $42.00 | $210.0K | 135 | 1.3K |
| LQDA | CALL | TRADE | NEUTRAL | 01/30/26 | $5.0 | $2.3 | $3.8 | $42.00 | $189.2K | 135 | 851 |
| LQDA | CALL | TRADE | BEARISH | 01/23/26 | $4.1 | $1.25 | $2.0 | $38.00 | $179.4K | 3.0K | 1.0K |
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Following our analysis of the options activities associated with Liquidia, we pivot to a closer look at the company's own performance.
Where Is Liquidia Standing Right Now?
- Trading volume stands at 872,768, with LQDA's price down by -1.97%, positioned at $40.26.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 54 days.
What The Experts Say On Liquidia
In the last month, 3 experts released ratings on this stock with an average target price of $51.0.
- Reflecting concerns, an analyst from BTIG lowers its rating to Buy with a new price target of $49.
- Reflecting concerns, an analyst from BTIG lowers its rating to Buy with a new price target of $49.
- Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Liquidia with a target price of $55.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
